---
title: "Chardan Capital Keeps Their Buy Rating on SAB Biotherapeutics (SABS)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286193633.md"
description: "Chardan Capital has maintained a Buy rating on SAB Biotherapeutics (SABS) with a price target of $14.00, as reported by analyst Keay Nakae. Nakae, a 3-star analyst with a 38.80% success rate, also covers other healthcare stocks. Previously, H.C. Wainwright assigned a Buy rating to SABS with a price target of $10.00."
datetime: "2026-05-13T03:55:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286193633.md)
  - [en](https://longbridge.com/en/news/286193633.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286193633.md)
generator: "portal-rs"
---

# Chardan Capital Keeps Their Buy Rating on SAB Biotherapeutics (SABS)

In a report released yesterday, Keay Nakae from Chardan Capital reiterated a Buy rating on SAB Biotherapeutics, with a price target of $14.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Nakae is a 3-star analyst with an average return of 2.5% and a 38.80% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Alto Neuroscience, Inc., Alnylam Pharma, and Ibio.

In a report released on May 11, H.C. Wainwright also assigned a Buy rating to the stock with a $10.00 price target.

### Related Stocks

- [SABS.US](https://longbridge.com/en/quote/SABS.US.md)
- [ANRO.US](https://longbridge.com/en/quote/ANRO.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [IBIO.US](https://longbridge.com/en/quote/IBIO.US.md)
- [SABSW.US](https://longbridge.com/en/quote/SABSW.US.md)

## Related News & Research

- [Craig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)](https://longbridge.com/en/news/289926672.md)
- [Chardan Capital Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)](https://longbridge.com/en/news/296873445.md)
- [Repligen CEO, CFO to join Wells Fargo Healthcare Conference analyst discussion](https://longbridge.com/en/news/297037160.md)
- [BTIG Keeps Their Buy Rating on Shift4 Payments (FOUR)](https://longbridge.com/en/news/297163377.md)
- [Nantahala Capital Management LLC Takes $6.05 Million Position in Lexeo Therapeutics, Inc. $LXEO](https://longbridge.com/en/news/297400560.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**